$65.21
-0.29-0.44%
Comments
Loading...
Haemonetics Stock Guidance | NYSE:HAE | Benzinga
Haemonetics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
Data brought to you by Benzinga APIs
FAQ
What is the most recent guidance for Haemonetics (HAE)?
The most recent guidance for Haemonetics (HAE) was reported on February 6, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $4.50 to $4.70, compared to the estimated EPS of $4.59. Additionally, Haemonetics forecasted revenue between $1.35B and $1.37B for the quarter.
Browse guidance and forecast on all stocks.